The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis
Open accessAbstract
Background and Aims: Most patients with HCC are diagnosed at a late stage, highlighting the need for more accurate surveillance tests. Although biomarkers for HCC early detection have promising data in Phase 2 case–control studies, evaluation in cohort studies is critical prior to adoption in practice. We leveraged a prospective cohort of patients with Child‐Pugh A or B cirrhosis who were followed until incident HCC, liver transplantation, death, or loss to follow‐up. We used a prospective specimen collection, retrospective, blinded evaluation design for biomarker evaluation of GALAD (gender × age × log alpha‐fetoprotein [AFP] × des‐gamma‐carboxy prothrombin), longitudinal GALAD, and the HCC Early Detection Screening (HES) algorithm—compared to AFP—using patient‐level sensitivity and screening‐level specificity. Approach and Results: Of 397 patients with cirrhosis, 42 developed HCC (57.1% early stage) over a median of 2.0 years. Longitudinal GALAD had the highest c‐statistic for HCC detection (0.85; 95% CI, 0.77–0.92) compared to single–time point GALAD (0.79; 95% CI, 0.71–0.87), AFP (0.77; 95% CI, 0.69–0.85), and HES (0.76; 95% CI, 0.67–0.83). When specificity was fixed at 90%, the sensitivity for HCC of single–time point and longitudinal GALAD was 54.8% and 66.7%, respectively, compared to 40.5% for AFP. Sensitivity for HCC detection was higher when restricted to patients with biomarker assessment within 6 months prior to HCC diagnosis, with the highest sensitivities observed for single–time point GALAD (72.0%) and longitudinal GALAD (64.0%), respectively. Sensitivity of single–time point and longitudinal GALAD for early‐stage HCC was 53.8% and 69.2%, respectively. Conclusion: GALAD demonstrated high sensitivity for HCC detection in a cohort of patients with cirrhosis. Validation of these results is warranted in large Phase 3 data sets.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686 · cited 1×
“Biomarker evaluation was performed using a prospective specimen collection, retrospective, blinded evaluation design.[17] For this study, biomarkers were evaluated at multiple time points during follow- up, so we were able to evaluate algorithms that incorporate serial biomarker measurements into the screening decisio…”
MethodWolf, E., Rich, N. E., Marrero, J. A., Parikh, N. D., & Singal, A. G. (2021) · Hepatology · doi:10.1002/hep.31309 · Cited by 333
Self-citationAtiq, O., Tiro, J., Yopp, A. C., Muffler, A., Marrero, J. A., Parikh, N. D., Murphy, C., McCallister, K., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28895 · Cited by 266
Self-citationFarvardin, S., Patel, J., Khambaty, M., Yerokun, O. A., Mok, H., Tiro, J. A., Yopp, A. C., Parikh, N. D., Marrero, J. A., & Singal, A. G. (2017) · Hepatology · doi:10.1002/hep.28770 · Cited by 185
Self-citation
Cited by
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Singal, A. G., Llovet, J. M., Yarchoan, M., Mehta, N., Heimbach, J. K., Dawson, L. A., Jou, J. H., Kulik, L. M., Agopian, V. G., Marrero, J. A., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000466 · Cited by 2,052
“…3 Sensitivity 62% Specificity 90% DCP [69] 3 Sensitivity 40% Specificity 81% Multitarget algorithm [70] 2 Sensitivity 82% Specificity 87% GALAD [ 71 ] 2/3 Sensitivity 54 – 72% Specificity 90% Doylestown plus [72] 2/3 Sensitivity 90% Specificity 95% Turcotte-Pugh B or C cirrhosis, so this may be…”
Self-citationCirculating biomarkers in the diagnosis and management of hepatocellular carcinoma
Johnson, P., Zhou, Q., Dao, D. Y., & Lo, Y. M. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00620-y · Cited by 320
Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0824 · Cited by 306
Self-citationBiomarkers for diagnosis and therapeutic options in hepatocellular carcinoma
Chan, Y.-T., Zhang, C., Wu, J., Lu, P., Xu, L., Yuan, H., Feng, Y., Chen, Z.-S., & Wang, N. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02101-z · Cited by 281
Opportunities to address gaps in early detection and improve outcomes of liver cancer
McMahon, B., Cohen, C., Brown Jr, R. S., El-Serag, H., Ioannou, G. N., Lok, A. S., Roberts, L. R., Singal, A. G., & Block, T. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad034 · Cited by 44
Self-citation
Metadata
- Authors
- Singal, A. G., Tayob, N., Mehta, A., Marrero, J. A., El‐Serag, H., Jin, Q., Saenz de Viteri, C., Fobar, A., & Parikh, N. D.
- Venue
- Hepatology
- Published
- 2021-12-17
- Volume
- 75
- Issue
- 3
- Pages
- 541-549
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W3204744768
- Cited by
- 173
- References
- 4
- FWCI
- 13.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. https://app.cochat.ai/papers/10.1002/hep.32185
- The paper
- Singal, A. G., Tayob, N., Mehta, A., Marrero, J. A., El‐Serag, H., Jin, Q., Saenz de Viteri, C., Fobar, A., & Parikh, N. D. (2022). GALAD demonstrates high sensitivity for HCC surveillance in a cohort of patients with cirrhosis. Hepatology. https://doi.org/10.1002/hep.32185
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.